

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

NMPA APPROVED NDA OF 愛達羅® (EBDAROKIMAB, IL-12/IL-23)

This announcement is made by Akeso, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the National Medical Products Administration (“**NMPA**”) of China has recently approved the new drug application (“**NDA**”) of 愛達羅® (ebdarokimab, IL-12/IL-23) for the treatment of moderate to severe plaque psoriasis in adult patients.

Ebdarokimab is the Company’s first Class 1 new drug approved for autoimmune diseases and the second non-oncology new drug to obtain marketing approval following ebronucimab. The approval of NDA is based on a total of 5 clinical studies of ebdarokimab in patients with moderate to severe plaque psoriasis in China. Two pivotal phase III clinical studies demonstrated ebdarokimab’s efficacy and safety at both 16-week and 52-week clinical results.

The results showed:

- Positive short-term efficacy: Patients receiving ebdarokimab injection 135mg with two doses at week 0 and week 4 showed a significantly positive efficacy, with a PASI 75 response rate of 79.4% at week 16.
- Sustained long-term efficacy: Patients receiving ebdarokimab injection 135mg every 12 weeks (Q12W) for maintenance therapy achieved long-term durable efficacy, with a PASI 75 response rate of 77.9% at week 52.
- Significant improvement in Quality-of-Life (QoL): Long-term maintenance treatment with ebdarokimab significantly improved patients’ QoL, alongside the improvement of skin lesions.

- Good safety profile: The incidence of adverse events was low and manageable.
- Convenience of administration: Ebdarokimab, administered as four subcutaneous injections annually, provides treatment convenience and long-term and stable improvements in treatment efficacy and patients' QoL.

The results have been presented at 2023 European Academy of Dermatology and Venereology (“**EADV**”) and 2024 EADV.

Psoriasis is a chronic and relapsing autoimmune disorder, which needs lifelong management upon disease onset, imposing substantial therapeutic and economic burdens on patients. Traditional therapies are frequently associated with suboptimal efficacy and high incidence of adverse effects, leading to poor patient tolerability. In China, the psoriatic population exceeds 6.7 million and continues to grow annually, requiring long-term pharmacological interventions that collectively exacerbate the disease burden.

Ebdarokimab, as China's first and only commercialized IL-12/IL-23 monoclonal antibody, demonstrates superior clinical efficacy and favorable safety profiles coupled with reduced dosing frequency. This innovative drug holds significant potential to provide cost-effective and patient-centric therapeutic solutions with enhanced efficacy and convenience for Chinese patients with moderate to severe psoriasis.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and executive director

Hong Kong, April 21, 2025

As of the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive director, Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Dr. ZHANG Peng as executive directors, Mr. XIE Ronggang as non-executive director, and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive directors.